22nd Century Group, Inc. (Nasdaq: XXII) is an agricultural biotechnology company focused on leveraging advanced plant breeding and genetic engineering technologies to decrease harm and enhance health and wellness. The company is a leader in reducing nicotine content in tobacco plants to minimally or non-addictive levels, commercializing its VLN® brand cigarettes with 95% less nicotine than conventional cigarettes. Additionally, 22nd Century Group is involved in research and development of proprietary hemp/cannabis plant lines for medical, therapeutic, and agricultural applications, aiming to optimize cannabinoid and terpene profiles.
The Buffalo headquarters serves as the primary center for corporate management, strategic decision-making, investor relations, regulatory affairs, and administrative support for the company's research, development, and commercialization activities.
The headquarters is located in the 500 Seneca Street building, a large, historically significant former industrial complex that has been redeveloped into a modern mixed-use facility. It offers contemporary office spaces with various amenities.
The work culture at 22nd Century Group's headquarters likely emphasizes innovation, scientific rigor, and a mission-driven approach to public health and plant-based solutions. It fosters a collaborative environment geared towards achieving breakthroughs in agricultural biotechnology.
Buffalo's strategic location, access to research institutions, and New York State's support for biotech industries make it a fitting base for 22nd Century Group's operations. The HQ centralizes leadership for its pioneering work in tobacco harm reduction and plant science.
22nd Century Group supports global functions including research collaborations, intellectual property management, and the international expansion of its VLN® reduced nicotine tobacco products. The company has initiated sales in international markets such as South Korea, Switzerland, and Chile, and is exploring further expansion opportunities in Europe and Asia-Pacific to address public health concerns related to smoking worldwide.
500 Seneca Street, Suite 507
Buffalo
New York
USA
Address: 650 Interstate Drive, Mocksville, NC 27028
Located in a region with a long history in tobacco cultivation and manufacturing, the Mocksville facility leverages existing infrastructure and skilled workforce to support the commercial scale-up and distribution of VLN® cigarettes across the United States and internationally.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, 22nd Century Group, Inc.' leadership includes:
22nd Century Group, Inc. has been backed by several prominent investors over the years, including:
In the past year, 22nd Century Group has made strategic changes to its executive team, including appointing a new Chief Scientific Officer and solidifying its CEO and CFO leadership, to drive its focus on plant-based biotechnology and reduced nicotine tobacco.
Discover the tools 22nd Century Group, Inc. uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
For professional communication with 22nd Century Group, the most commonly observed email format is the first initial of the employee's name followed by their full last name.
[first_initial][last]@xxiicentury.com
Format
jdoe@xxiicentury.com
Example
85%
Success rate
Business Wire • May 21, 2024
22nd Century Group announced its financial results for Q1 2024, highlighting advancements in its VLN® reduced nicotine cigarette commercialization, operational optimization, and plant research initiatives. The company reiterated its commitment to achieving profitability and expanding market share for its innovative tobacco products....more
GlobeNewswire • January 23, 2024
22nd Century Group announced the appointment of Dr. Steven Przybyla as its new Chief Scientific Officer. Dr. Przybyla, with significant experience in plant science and biotechnology, will lead the company's R&D efforts for its tobacco and hemp/cannabis programs, aiming to drive innovation and product development....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including 22nd Century Group, Inc., are just a search away.